Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study

BACKGROUND: The combination of BRAF and MEK inhibitors has become standard of care in the treatment of metastatic BRAF V600-mutated melanoma. Clinical factors for an early prediction of tumor response are rare. The present study investigated the association between the development of an early exanth...

Descripción completa

Detalles Bibliográficos
Autores principales: Kähler, Katharina C., Gutzmer, Ralf, Meier, Friedegrund, Zimmer, Lisa, Heppt, Markus, Gesierich, Anja, Thoms, Kai-Martin, Utikal, Jochen, Hassel, Jessica C., Loquai, Carmen, Pföhler, Claudia, Heinzerling, Lucie, Kaatz, Martin, Göppner, Daniela, Pflugfelder, Annette, Bohne, Ann-Sophie, Satzger, Imke, Reinhardt, Lydia, Placke, Jan-Malte, Schadendorf, Dirk, Ugurel, Selma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183381/
https://www.ncbi.nlm.nih.gov/pubmed/34109122
http://dx.doi.org/10.3389/fonc.2021.672172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183381/
https://www.ncbi.nlm.nih.gov/pubmed/34109122
http://dx.doi.org/10.3389/fonc.2021.672172

Ejemplares similares